Ensuring management of vascular risk factors after stroke

Reviews in Neurological Diseases

Volumn 3, Issue 3, 2006, Pages 93-100

  Ovbiagele, Bruce ^a   Saver, Jeffrey L ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Evidence practice gap; GWTG; Ischemic stroke; PROTECT; Secondary stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; DRUG INDICATION; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MEDICAL CARE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; TOTAL QUALITY MANAGEMENT; VASCULAR DISEASE;

CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; PATIENT DISCHARGE; PRACTICE GUIDELINES; RECURRENCE; RISK FACTORS;

EID: 33749376494     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. NINDS rt-PA Stroke Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Nilasena D, Kresowik TF, Wiblin RT, et al. Assessing patterns of t-PA use in acute stroke [abstract]. Stroke. 2002;33:354.
3. Gorelick PB. Stroke prevention: windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal. Neuroepidemiology. 1997; 16:163-173.
4. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-Sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
5. Holloway R, Benesch C, Rush SR. Stroke prevention: narrowing the evidence-practice gap. Neurology. 2000;54:1899-1906.
6. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36:1232-1240.
7. Thorn T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
8. Coull A, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328:326.
9. Hankey G. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis. 2003;16(suppl 1):14-19.
10. Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year survival after first-ever stroke in the Perth community stroke study. Stroke. 2003;34:1842-1846.
11. Coutts SB, Hill MD, Simon JE, et al. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology. 2005;65:513-517.
12. Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16:280-285.
13. Arima H, Tzourio C, Butcher K, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006;37:1497-1502.
14. Adams R, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke. 2003;34: 2310-2322.
15. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
16. Fonarow G. Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. Vasc Med. 2002;7:187-194.
17. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36:1232-1240.
18. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001;161:1621-1628.
19. Ovbiagele B, Hills NK, Saver JL, Johnston SC. Antihypertensive medications prescribed at discharge after an acute ischemic cerebrovascular event. Stroke. 2005;36:1944-1947.
20. Mullard AJ, Reeves MJ, Jacobs BS, et al. Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry. Stroke. 2006;37:44-49.
21. University Health-System Consortium. Ischemic Stroke Clinical Benchmarking Project Clinical Database Analysis-2001: University Health-System Consortium Ischemic Stroke Database Report #3. Oak Brook, IL: University HealthSystem Consortium; 2002.
22. Isles C, Campbell N, Stuckey N. Secondary prevention of CHD and the National Service Framework: barriers to implementation. Cardiabetes. 2001;1:11-17.
23. Ollivier V, Thelcide C, Simon C, Favier M. Standardized order form for investigational drugs: effect on completeness of the prescription. Pharm World Sci. 2004;26:178-179.
24. Helman DL, Sherner JH, Fitzpatrick TM, et al. Effect of standardized orders and provider education on head-of-bed positioning in mechanically ventilated patients. Crit Care Med. 2003;31:2285-2290.
25. California Acute Stroke Pilot Registry Investigators. The impact of standardized stroke orders on adherence to best practices. Neurology. 2005;65:360-365.
26. Fonarow G, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819-822.
27. Aronow H, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med. 2003;163:2576-2582.
28. Muhlestein J, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 2001;87:257-261.
29. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106: 1893-1900.
30. Thomson MA, Oxman AD, Haynes RB, et al. Local opinion leaders to improve health professional practice and health care outcomes (Cochrane Review). Oxford, UK: The Cochrane Library Update Software; 1999.
31. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA. 1990;263:549-556.
32. Balas EA, Austin SM, Mitchell JA, et al. The clinical value of computerized information services: a review of 98 randomized clinical trials. Arch Fam Med. 1996;5:271-278.
33. Grilli R. Media have key role in shaping use of health services. BMJ. 1999;319:786-787.
34. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Audit and feedback versus alternative strategies: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2000;(2):CD000260.
35. LaBresh K, Schwamm L, Albright D, et al. Does Get With The Guidelines improve secondary prevention in patients hospitalized with ischemic stroke or TIA? [abstract]. Stroke. 2005; 36:416.
36. Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology. 2004;63:1217-1222.
37. JCAHO Stroke Disease-Specific Care performance measure set. Available at: http://www. jointcommission.org/CertificationPrograms/PrimaryStrokeCenters/ stroke_measure_set.htm. Accessed June 15, 2006.
38. Kargman DE, Tuck C, Berglund L, et al. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis. 1998;139:391-399.
39. Gore J, Goldberg RJ, Matsumoto AS, et al. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol. 1984;54:722-725.
40. Carlberg B, Asplund K, Hagg E. Factors influencing admission blood pressure levels in patients with acute stroke. Stroke. 1991;22:527-530.
41. Schrader J, Lüders S, Kulschewski A, et al. The ACCESS study, evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699-1703.
42. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
43. Progressive Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
44. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
45. Dergalust S, Rofail M, Bateshansky DS, et al. The incidence of discontinuation of extended release dipyridamole/aspiiin, clopidogrel, and warfarin for the secondary prevention of stroke [abstract]. Neurology. 2003;60:A498.
46. Hankey G, Jamrozik K, Broadhurst, RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke. 1998;29:2491-2500.
47. Ovbiagele B, Saver JL, Fredieu A, et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke. 2004;35:2879-2883.
48. Ovbiagele B, Kidwell CS, Seko S, et al. Treatment adherence rates one year after initiation of a systematic hospital-based stroke prevention program. Cerebrovasc Dis. 2005;20:280-282.
49. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-1195.
50. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation. 2002;105:2861-2866.
51. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002;39: 83-89.
52. Kimmelstiel C, Levine D, Perry K, et al. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation. 2004;110:1450-1455.